menu
    • menu
    [{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Miravo Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aralez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aralez Pharmaceuticals \/ Miravo Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Aralez Pharmaceuticals \/ Miravo Healthcare"},{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Aralez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aralez Pharmaceuticals \/ Aralez Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Aralez Pharmaceuticals \/ Aralez Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Aralez Pharmaceuticals

    Menu

    Aralez Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aralez Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aralez Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Miravo Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Old...

                            Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.

                            Product Name : Blexten

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2022

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Miravo Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aralez Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aralez Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Recipient : Innovaderm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

                            Details : Acitretin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2012

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Innovaderm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth